Neuroendocrine Tumors Drug Development Pipeline: 2025 Insights

According to DelveInsight's evaluation, the worldwide Neuroendocrine Tumors pipeline comprises 70+ prominent organizations actively engaged in advancing 75+ therapeutic candidates for Neuroendocrine Tumors management, featuring comprehensive analysis of Clinical Studies, Treatment Modalities, Mechanisms of Action, Administration Routes, and Developmental Progress as examined by DelveInsight.

The Neuroendocrine Tumors Pipeline analysis encompasses thorough commercial and clinical evaluation of pipeline assets spanning from pre-clinical development stages through to market authorization. The analysis additionally provides comprehensive descriptions of each drug candidate, incorporating details on mechanisms of action, clinical investigations, regulatory submissions (where applicable), and developmental activities including technological innovations, partnerships, mergers and acquisitions, financial backing, regulatory designations, and additional product-specific information.

"Neuroendocrine Tumors Pipeline Insight, 2025]" analysis by DelveInsight presents comprehensive perspectives on the current clinical development landscape and expansion potential within the Neuroendocrine Tumors Market.

Key Highlights from the Neuroendocrine Tumors Pipeline Analysis:

• Organizations worldwide are rigorously pursuing the development of innovative Neuroendocrine Tumors therapeutic solutions with significant achievements demonstrated throughout recent years.

• Neuroendocrine Tumors pharmaceutical developers operating in this therapeutic area include Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, IITM Isotope Technologies Munich, Camurus, RayzeBio, Fundacion de investigacion HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, among others, who are advancing treatments for Neuroendocrine Tumors management.

• Investigational Neuroendocrine Tumors treatments across various developmental stages include LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (lanreotide), AFINITOR (everolimus), (sunitinib malate), DEMSER Capsule (metyrosine), WELIREG (belzutifan/MK-6482), ITM-11, CAM2029, RYZ101, 177Lu-Dotatate, AlphaMedix, Lutetium[177Lu], 64Cu-SARTATE, 177Lu-edotreotide PRRT, PM8002, nab-sirolimus, [68Ga]Ga-DOTA-TATE, CVM-1118, Surufatinib, [212Pb]VMT--NET, 68Ga-DOTATOC, Pembrolizumab, among others, which are anticipated to substantially influence the Neuroendocrine Tumors market landscape in forthcoming years.

• In October 2025, Belzutifan (Welireg) exhibited sustained therapeutic responses in individuals with advanced pheochromocytoma or paraganglioma (PPGL) during a single-arm Phase II investigation, supporting the FDA's recent regulatory approval of this agent for these uncommon neuroendocrine malignancies. Within this study, 26% (95% CI: 17-38) of the 72 enrolled subjects achieved confirmed objective responses—all categorized as partial—satisfying the primary efficacy measure. Furthermore, 58% of participants demonstrated stable disease status, yielding an overall disease control rate of 85%, as reported by Dr. Camilo Jimenez from MD Anderson Cancer Center, Houston.

• In March 2025, Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) granted approval for CABOMETYX Registered (cabozantinib) for two additional indications: 1) for adults and adolescent patients aged 12 years and above with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) for the identical age demographic with previously treated, unresectable, locally advanced or metastatic well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Neuroendocrine tumors (NETs) represent a heterogeneous collection of malignancies arising from neuroendocrine cells throughout the digestive tract and other anatomical sites, encompassing the pancreas and pulmonary system.

• In February 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotechnology enterprise, disclosed promising preliminary results from its Phase III COMPETE investigation. This study evaluated ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiotherapeutic agent, in subjects with inoperable, progressing Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The findings demonstrated that ITM-11 achieved a statistically significant and clinically relevant enhancement in progression-free survival (PFS) relative to everolimus, an established standard therapeutic option.

• In January 2025, Cabozantinib (Cabometyx) exhibited a substantial enhancement in progression-free survival (PFS) versus placebo in individuals with extrapancreatic neuroendocrine tumors (NETs) arising from the gastrointestinal (GI) tract who had undergone prior therapy. Results from the Phase 3 CABINET investigation (NCT03375320), presented at the 2025 Gastrointestinal Cancers Symposium, indicated that the PFS benefit remained consistent across multiple clinical subgroups—with the exception of subjects with non-midgut GI primary malignancies.

Understanding Neuroendocrine Tumors

Neuroendocrine tumors (NETs) represent an uncommon cancer category that originates from neuroendocrine cells, which possess characteristics of both neuronal cells and hormone-secreting cells. These malignancies can manifest anywhere throughout the body but predominantly occur in the gastrointestinal system, pancreas, and pulmonary organs. NETs may exhibit slow progression (benign characteristics) or aggressive behavior (malignant presentation) and might secrete hormones triggering diverse clinical manifestations including flushing, diarrhea, and respiratory wheezing. Early identification presents significant challenges, and therapeutic approaches generally encompass surgical intervention, targeted molecular therapies, or endocrine-based treatments depending on tumor anatomical location and disease stage.

Access a Free Sample PDF Analysis to learn more about @ Neuroendocrine Tumors Pipeline Therapeutic Evaluation

Investigational Neuroendocrine Tumors Therapeutics Across Various Clinical Development Phases Comprise:

• LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis

• SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

• AFINITOR (everolimus): Novartis

• (sunitinib malate): Pfizer

• DEMSER Capsule (metyrosine): Bausch Health and Ono Pharma

• WELIREG (belzutifan/MK-6482): Merck

• ITM-11: ITM Isotope Technologies Munich

• CAM2029: Camurus

• RYZ101: RayzeBio

• 177Lu-Dotatate: Fundacion de investigacion HM

• AlphaMedix: Radiomedix, Inc.

• Lutetium[177Lu]: Sinotau Pharmaceutical

• 64Cu-SARTATE: Clarity Pharmaceuticals

• 177Lu-edotreotide PRRT: ITM Solucin GmbH

• PM8002: Biotheus Inc.

• nab-sirolimus: Aadi Bioscience, Inc.

• [68Ga]Ga-DOTA-TATE: Novartis

• CVM-1118: TaiRx, Inc.

• Surufatinib: Hutchmed

• [212Pb]VMT--NET: Perspective Therapeutics

• Surufatinib: Hutchmed

• 68Ga-DOTATOC: Jiangsu HengRui Medicine

• RYZ101: RayzeBio, Inc.

• Pembrolizumab: Nicholas Fidelman, MD

Neuroendocrine Tumors Administration Routes

The Neuroendocrine Tumors pipeline analysis delivers therapeutic classification of pipeline candidates by Administration Route. Candidates have been organized across various administration methods, including:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Neuroendocrine Tumors Molecular Classifications

Neuroendocrine Tumors Assets have been categorized across various Molecular classifications, including:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Neuroendocrine Tumors Pipeline Treatment Evaluation

• Neuroendocrine Tumors Classification by Product Category

• Neuroendocrine Tumors By Development Stage and Product Category

• Neuroendocrine Tumors Classification by Administration Route

• Neuroendocrine Tumors By Development Stage and Administration Route

• Neuroendocrine Tumors Classification by Molecular Type

• Neuroendocrine Tumors by Development Stage and Molecular Type

DelveInsight's Neuroendocrine Tumors Analysis encompasses approximately 75+ assets across different stages of clinical investigation including:

• Advanced-stage candidates (Phase III)

• Intermediate-stage candidates (Phase II)

• Initial-stage candidates (Phase I)

• Pre-clinical and Discovery phase programs

• Terminated & Inactive programs

• Route of Administration

Additional Neuroendocrine Tumors product information is included in the analysis. Access the Neuroendocrine Tumors pipeline analysis to discover more about the investigational @ Neuroendocrine Tumors treatments

Leading Organizations in the Neuroendocrine Tumors Treatment Market:

Principal organizations advancing therapeutics for Neuroendocrine Tumors include - Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, among others.

Neuroendocrine Tumors Pipeline Examination:

The Neuroendocrine Tumors pipeline analysis delivers perspectives on:

• The analysis offers comprehensive insights regarding organizations advancing treatments for Neuroendocrine Tumors management with aggregate therapeutic candidates developed by individual companies for this indication.

• It evaluates various therapeutic candidates categorized into initial-stage, intermediate-stage, and advanced-stage development for Neuroendocrine Tumors Treatment.

• Neuroendocrine Tumors principal organizations engaged in targeted therapeutic advancement with corresponding active and inactive (dormant or terminated) programs.

• Neuroendocrine Tumors Therapeutics under investigation classified by development phase, administration route, target receptor, monotherapy or combination approaches, distinct mechanisms of action, and molecular classification.

• Comprehensive examination of partnerships (inter-company collaborations and company-academic institution partnerships), licensing agreements and funding arrangements for future progression of the Neuroendocrine Tumors market.

The analysis is constructed utilizing data and intelligence obtained from the researcher's proprietary databases, organizational/institutional websites, clinical trial registries, scientific conferences, regulatory filings, investor communications, and highlighted press announcements from organizational/institutional websites and industry-focused third-party resources.

Download Sample PDF Analysis to learn more about @ Neuroendocrine Tumors therapeutics and treatments

Neuroendocrine Tumors Pipeline Market Growth Factors

• Increasing disease prevalence, expanding Research and Development Initiatives represent significant factors propelling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Challenges

• Nevertheless, insufficient Awareness and Under-detection, disease heterogeneity and Complexity along with additional factors present impediments to Neuroendocrine Tumors Market expansion.

Parameters of Neuroendocrine Tumors Pipeline Drug Analysis

• Geographic Coverage: Global

• Principal Neuroendocrine Tumors Organizations: Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, IITM Isotope Technologies Munich, Camurus, RayzeBio, Fundacion de investigacion HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, among others

• Principal Neuroendocrine Tumors Treatment Assets: LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (lanreotide), AFINITOR (everolimus), (sunitinib malate), DEMSER Capsule (metyrosine), WELIREG (belzutifan/MK-6482), ITM-11, CAM2029, RYZ101, 177Lu-Dotatate, AlphaMedix, Lutetium[177Lu], 64Cu-SARTATE, 177Lu-edotreotide PRRT, PM8002, nab-sirolimus, [68Ga]Ga-DOTA-TATE, CVM-1118, Surufatinib, [212Pb]VMT--NET, 68Ga-DOTATOC, Pembrolizumab, among others

• Neuroendocrine Tumors Treatment Evaluation: Neuroendocrine Tumors currently approved and Neuroendocrine Tumors investigational therapies

• Neuroendocrine Tumors Market Forces: Neuroendocrine Tumors market growth catalysts and Neuroendocrine Tumors market obstacles

Request Sample PDF Analysis for @ Neuroendocrine Tumors Pipeline Evaluation and clinical investigations

Report Contents

1. Neuroendocrine Tumors Analysis Introduction

2. Neuroendocrine Tumors Executive Overview

3. Neuroendocrine Tumors Disease Overview

4. Neuroendocrine Tumors- Strategic Perspective In-depth Commercial Evaluation

5. Neuroendocrine Tumors Pipeline Treatment Options

6. Neuroendocrine Tumors Advanced Stage Assets (Phase II/III)

7. Neuroendocrine Tumors Intermediate Stage Assets (Phase II)

8. Neuroendocrine Tumors Initial Stage Assets (Phase I)

9. Neuroendocrine Tumors Preclinical Development Assets

10. Neuroendocrine Tumors Treatment Evaluation

11. Neuroendocrine Tumors Discontinued Assets

12. Organization-Academic Institution Partnerships (Licensing/Collaboration) Examination

13. Neuroendocrine Tumors Principal Organizations

14. Neuroendocrine Tumors Principal Assets

15. Neuroendocrine Tumors Unaddressed Medical Needs

16. Neuroendocrine Tumors Market Growth Catalysts and Obstacles

17. Neuroendocrine Tumors Future Outlook and Summary

18. Neuroendocrine Tumors Expert Perspectives

19. Supplementary Materials

20. About DelveInsight

About DelveInsight

DelveInsight operates as a premier Business Advisory and Market Intelligence organization focused exclusively on life sciences sectors. It supports pharmaceutical enterprises by delivering comprehensive end-to-end solutions to enhance organizational performance. It additionally provides Healthcare Advisory Services, which facilitate market intelligence to accelerate commercial expansion and address challenges through pragmatic methodologies.

Contact Us

Kanishk

kkumar@delveinsight.com